Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial

作者：Caicun Zhou, Ziping Wang, Meili Sun, Lejie Cao, Zhiyong Ma, Rong Wu, Yan Yu, Wenxiu Yao, Si Sun, J. Chen, Wu Zhuang, Jiuwei Cui, Xueqin Chen, You Lu, Hong Shen, Chunhong Hu, Jiwei Liu, Yunpeng Liu, Mengzhao Wang, Xingya Li, Ping Sun, Yongqian Shu, Jianying Zhou, Jingzhang Li, Kangsheng Gu, Changli Wang, Hui Zhao, X.-C. Zhang, Chunling Liu, Hui Yang, Xiaochun Zhang, Rui Ma, Lin Li, Li Liang, Man Li, Jingru Wang, Qiang Wang, Bo Wang, Hangjun Dai, Qingmei Shi, Jason Yang · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(25)00198-6 · 被引用次数：16 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment